AI Engines For more Details: Perplexity Kagi Labs You
Antifungal Activity: Voriconazole belongs to the azole class of antifungal agents and exhibits broad-spectrum activity against various fungal pathogens, including Candida species, Aspergillus species, and certain other molds.
Treatment of Invasive Fungal Infections: Voriconazole is indicated for the treatment of invasive fungal infections, including invasive aspergillosis, candidemia in non-neutropenic patients, esophageal candidiasis, and serious fungal infections caused by Scedosporium and Fusarium species.
Mechanism of Action: Voriconazole works by inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes. By disrupting fungal cell membrane integrity, voriconazole impairs fungal growth and replication, leading to the death of susceptible fungal organisms.
High Efficacy: Voriconazole is considered one of the first-line agents for the treatment of invasive aspergillosis, a life-threatening fungal infection commonly affecting immunocompromised patients, such as those with hematologic malignancies or recipients of hematopoietic stem cell or solid organ transplants.
Pharmacokinetics: Voriconazole is available in both oral and intravenous formulations. It exhibits good oral bioavailability and achieves therapeutic concentrations in various body tissues and fluids, including lung tissue, cerebrospinal fluid, and vitreous humor.
Adverse Effects: Common adverse effects associated with voriconazole therapy include visual disturbances (e.g., blurred vision, photophobia), liver enzyme abnormalities, gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea), and skin rashes. Visual disturbances, including changes in color perception and photopsia (flashes of light), are particularly common and may necessitate dose adjustments or discontinuation of treatment.
Drug Interactions: Voriconazole is metabolized primarily by the cytochrome P450 (CYP) enzyme system, particularly the CYP2C19 and CYP3A4 isoenzymes. Consequently, voriconazole has the potential to interact with other medications that are substrates, inducers, or inhibitors of these enzymes, leading to altered plasma concentrations and potential toxicity or reduced efficacy of co-administered drugs.
QT Prolongation: Voriconazole has been associated with QT interval prolongation, which may predispose patients to cardiac arrhythmias, including torsades de pointes. Therefore, caution is advised when using voriconazole in patients with preexisting cardiac conditions or those receiving concomitant medications known to prolong the QT interval.
Hepatotoxicity: Voriconazole can cause liver enzyme elevations and, rarely, severe hepatotoxicity, including hepatic failure. Liver function tests should be monitored regularly during voriconazole therapy, and treatment should be discontinued if significant liver dysfunction occurs.
Monitoring and Management: Patients receiving voriconazole therapy require close monitoring of clinical and laboratory parameters, including visual acuity, liver function tests, and serum drug concentrations. Dose adjustments may be necessary based on individual patient factors, such as renal function, hepatic function, and drug interactions.
Patient Education: Patients prescribed voriconazole should be educated about the potential adverse effects of treatment, particularly visual disturbances, and instructed to report any new or worsening symptoms to their healthcare provider promptly.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.5 | 0.5 | |
| Acne | 0.3 | -0.3 | |
| ADHD | 4.4 | 0.3 | 13.67 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 3.3 | 2.1 | 0.57 |
| Allergies | 5.8 | 2.5 | 1.32 |
| Allergy to milk products | 1.8 | 1.6 | 0.13 |
| Alopecia (Hair Loss) | 1 | 1 | |
| Alzheimer's disease | 5.3 | 4.6 | 0.15 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 2.5 | 0.7 | 2.57 |
| Ankylosing spondylitis | 3.3 | 1.2 | 1.75 |
| Anorexia Nervosa | 1.6 | 2.3 | -0.44 |
| Antiphospholipid syndrome (APS) | 0.6 | 0.6 | |
| Asthma | 5.8 | 2.6 | 1.23 |
| Atherosclerosis | 2.1 | 1.4 | 0.5 |
| Atrial fibrillation | 3.2 | 1.6 | 1 |
| Autism | 7.2 | 7 | 0.03 |
| Autoimmune Disease | 1.2 | 1 | 0.2 |
| Barrett esophagus cancer | 0.6 | 0.3 | 1 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 1.3 | 1.3 | |
| Bipolar Disorder | 1.8 | 1.4 | 0.29 |
| Brain Trauma | 0.9 | 1.4 | -0.56 |
| Breast Cancer | 0.2 | 0.2 | |
| Cancer (General) | 0.9 | 1.7 | -0.89 |
| Carcinoma | 3.8 | 2.6 | 0.46 |
| Celiac Disease | 1.9 | 3.6 | -0.89 |
| Cerebral Palsy | 1.5 | 1.3 | 0.15 |
| Chronic Fatigue Syndrome | 3.2 | 4.2 | -0.31 |
| Chronic Kidney Disease | 3.1 | 1.5 | 1.07 |
| Chronic Lyme | 0.6 | 0.8 | -0.33 |
| Chronic Obstructive Pulmonary Disease (COPD) | 2.3 | 2 | 0.15 |
| Chronic Urticaria (Hives) | 1.5 | 0.2 | 6.5 |
| Coagulation / Micro clot triggering bacteria | 1.5 | 1.3 | 0.15 |
| Cognitive Function | 3.1 | 1.6 | 0.94 |
| Colorectal Cancer | 4.6 | 1.8 | 1.56 |
| Constipation | 1.5 | 0.7 | 1.14 |
| Coronary artery disease | 1.6 | 1.8 | -0.13 |
| COVID-19 | 8.8 | 7.1 | 0.24 |
| Crohn's Disease | 6.1 | 5 | 0.22 |
| Cushing's Syndrome (hypercortisolism) | 0.5 | 0.3 | 0.67 |
| cystic fibrosis | 1.7 | 1.9 | -0.12 |
| d-lactic acidosis (one form of brain fog) | 0.2 | 0.2 | |
| deep vein thrombosis | 1.2 | 1.4 | -0.17 |
| Denture Wearers Oral Shifts | 1.2 | 1.2 | |
| Depression | 8 | 8.8 | -0.1 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 2.2 | 1.4 | 0.57 |
| Endometriosis | 3 | 2.2 | 0.36 |
| Eosinophilic Esophagitis | 0.3 | 0.6 | -1 |
| Epilepsy | 2.6 | 1.6 | 0.63 |
| erectile dysfunction | 1.4 | 0.3 | 3.67 |
| Fibromyalgia | 2.3 | 1.6 | 0.44 |
| Functional constipation / chronic idiopathic constipation | 4.7 | 2.5 | 0.88 |
| gallstone disease (gsd) | 2.7 | 1.2 | 1.25 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.1 | 1.2 | -0.09 |
| Generalized anxiety disorder | 2.2 | 2.1 | 0.05 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 1.7 | 0.6 | 1.83 |
| Graves' disease | 1.9 | 3.3 | -0.74 |
| Gulf War Syndrome | 0.9 | 0.7 | 0.29 |
| Halitosis | 1.2 | 0.3 | 3 |
| Hashimoto's thyroiditis | 2.8 | 1 | 1.8 |
| Heart Failure | 3.8 | 1.4 | 1.71 |
| hemorrhagic stroke | 1.3 | 1.3 | |
| Hidradenitis Suppurativa | 1.2 | 0.3 | 3 |
| High Histamine/low DAO | 1 | 0.6 | 0.67 |
| hypercholesterolemia (High Cholesterol) | 0.6 | 0.2 | 2 |
| hyperglycemia | 1.7 | 1.5 | 0.13 |
| Hyperlipidemia (High Blood Fats) | 0.7 | 0.3 | 1.33 |
| hypersomnia | 0.4 | -0.4 | |
| hypertension (High Blood Pressure | 3.9 | 4.6 | -0.18 |
| Hypothyroidism | 0.1 | 0.7 | -6 |
| Hypoxia | 2.8 | 0.3 | 8.33 |
| IgA nephropathy (IgAN) | 1.6 | 2.6 | -0.63 |
| Inflammatory Bowel Disease | 5.3 | 6.6 | -0.25 |
| Insomnia | 1.9 | 3 | -0.58 |
| Intelligence | 1.1 | 1.1 | |
| Intracranial aneurysms | 1.4 | 0.6 | 1.33 |
| Irritable Bowel Syndrome | 4.9 | 4.6 | 0.07 |
| ischemic stroke | 2.8 | 1.4 | 1 |
| Juvenile idiopathic arthritis | 0.5 | 0.5 | |
| Liver Cirrhosis | 6.1 | 4.5 | 0.36 |
| Long COVID | 4.4 | 6.8 | -0.55 |
| Low bone mineral density | 1.1 | -1.1 | |
| Lung Cancer | 0.7 | 1.2 | -0.71 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 0.9 | 0.9 | 0 |
| ME/CFS with IBS | 0.5 | 2 | -3 |
| ME/CFS without IBS | 0.5 | 1.4 | -1.8 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 2.1 | 0.7 | 2 |
| Metabolic Syndrome | 5.6 | 6.9 | -0.23 |
| Mood Disorders | 7.4 | 6.8 | 0.09 |
| multiple chemical sensitivity [MCS] | 0.7 | 0.1 | 6 |
| Multiple Sclerosis | 5.2 | 3.3 | 0.58 |
| Multiple system atrophy (MSA) | 1 | 0.7 | 0.43 |
| myasthenia gravis | 0.9 | 0.7 | 0.29 |
| neuropathic pain | 3 | -3 | |
| Neuropathy (all types) | 0.5 | 2 | -3 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.7 | 0.7 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 4.9 | 5.1 | -0.04 |
| NonCeliac Gluten Sensitivity | 1.2 | 0.6 | 1 |
| Obesity | 8.3 | 6.6 | 0.26 |
| obsessive-compulsive disorder | 4.5 | 2.4 | 0.88 |
| Osteoarthritis | 1.8 | 1.8 | 0 |
| Osteoporosis | 2.2 | 1.5 | 0.47 |
| pancreatic cancer | 0.6 | 0.3 | 1 |
| Parkinson's Disease | 7 | 4.6 | 0.52 |
| Polycystic ovary syndrome | 4.5 | 2.6 | 0.73 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.6 | -2 |
| Premenstrual dysphoric disorder | 0.7 | 0.4 | 0.75 |
| primary biliary cholangitis | 1.2 | 1.3 | -0.08 |
| Primary sclerosing cholangitis | 2.1 | 2 | 0.05 |
| Psoriasis | 3 | 1.8 | 0.67 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 6.4 | 3.5 | 0.83 |
| Rosacea | 0.6 | 0.7 | -0.17 |
| Schizophrenia | 6.8 | 3.2 | 1.13 |
| scoliosis | 0.4 | 0.4 | 0 |
| Sjögren syndrome | 2.4 | 2.5 | -0.04 |
| Sleep Apnea | 2.2 | 1.6 | 0.38 |
| Slow gastric motility / Gastroparesis | 1 | 0.3 | 2.33 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.8 | 0.6 | 2 |
| Stress / posttraumatic stress disorder | 2.9 | 2.4 | 0.21 |
| Systemic Lupus Erythematosus | 3.6 | 1.8 | 1 |
| Tic Disorder | 0.9 | 1.2 | -0.33 |
| Tourette syndrome | 1 | 0.3 | 2.33 |
| Type 1 Diabetes | 3.7 | 3.8 | -0.03 |
| Type 2 Diabetes | 5.4 | 5.6 | -0.04 |
| Ulcerative colitis | 3.8 | 5 | -0.32 |
| Unhealthy Ageing | 2.7 | 2 | 0.35 |
| Vitiligo | 1.9 | 1.7 | 0.12 |
